IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

COPENHAGEN, Denmark, March 12, 2018 /PRNewswire/ -- IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win technology, announces it has entered into a collaborative agreement with Merck & Co.,...